Partner Content Partner Content Industry news with an exclusive interview by from Aerie Phar... Ophthalmic Drugs
Partner Content Partner Content Gene Therapy bringing new hope to patients and families Ophthalmic Drugs
Partner Content Partner Content Exclusive Interview Released from Santen for Ophthalmic Drug... Exclusive Interview Released from Santen
Partner Content Partner Content Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 20... Ophthalmic Drugs Conference London
Partner Content Partner Content Explore New Strategies for Treating Retinal Vascular Disease... Ophthalmic Drugs 2018
Partner Content Partner Content Explore the future of ocular gene editing and strategic drug... Ophthalmic Drugs Conference
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.